Collectively, these findings suggest that RES may be a potential drug that can be used to inhibit the progression of NSCLC by targeting and inhibiting the STAT3, HIF‐1α, and VEGF signaling pathway (Wang et al. 2020). Here, STAT3 is linked to non-small cell lung carcinoma.